

CliniMACS Prodigy® Adherent Cell Culture System GMP-compliant human pluripotent stem cell expansion process

Application

The CliniMACS Prodigy® Adherent Cell Culture System allows GMP-compliant and scalable human pluripotent stem cell (PSC) cultivation.

This application sheet gives an overview of the entire process and quality control assays, and provides information about the required materials. In addition, it elucidates the setup of the tubing set CliniMACS Prodigy TS 730 and the performance data.

Specifications

Process capacity: scalable (up to 5×10⁷ PSCs in

the CliniMACS Prodigy chamber;

up to 2×108 PSCs in one

Corning® CellSTACK® 1 Chamber;

up to 1×109 PSCs in one Corning CellSTACK 5 Chamber)

Starting cell

1×106 cells

number:

Final cell number: approx. 5×108 cells

Total process time:

10 days

Total hands-on time: approx. 5 h

Products

Consumables	Amount required
CliniMACS Prodigy® Instrument	1 piece
CliniMACS Prodigy TS 730	1 set
iPS-Brew GMP Medium	3 L
CliniMACS® PBS/EDTA Buffer (2×3 L)	3 L
MACS GMP Recombinant Human TGF-β1 (25 μg)	1 vial
1 m Tube Extension	2 pieces


Additional materials	Amount required
Additional materials	Amount required
Corning® CellSTACK® accessories, fill cap, 3.2 mm l.D. tubing, female Luer Lock with male luer plug	1 piece
Corning CellSTACK 5 Chamber	1 piece
Corning 1000 mL Easy Grip Polystyrene Storage Bottles with Dip Tube, with 0.2 µm MLL/FLL Filter*	2 pieces
Flexboy® Bag 50 mL, Inlet: Luer Lock male + cap, Outlet: Luer Lock female + cap, Sartorius	3 pieces
Flexboy Bag 500 mL, Inlet: Luer Lock male + cap, Outlet: Luer Lock female + cap, Sartorius	2 pieces
CTS™ TrypLE™ Select Enzyme, 100 mL, Thermo Fisher	300 mL
Defined Trypsin Inhibitor, 100 mL, Thermo Fisher	100 mL
Biolaminin 521 LN (LN521), 500 μg, BioLamina	4 vials
Thermo Fisher Biolaminin 521 LN (LN521), 500 µg,	

^{*}Used as alternative vessels for iPS-Brew GMP Medium


Process overview for PSC expansion

Pre-process (day –1)	Tubing set installation and priming ▼ Blocking of the tubing set with culture medium ▼ Coating of the CliniMACS Prodigy® chamber with LN521
Inoculation (day 0)	Inoculation of PSCs in the CliniMACS Prodigy chamber
Cultivation and medium change (day 2, 3, 4)	Medium change Coating of one CellSTACK 5 Chamber with LN521 (day 4)
Harvest and inoculation (day 5)	Automated harvest of P1 PSCs Sample collection for QC and cell counting Inoculation of P1 PSCs in one CellSTACK 5 Chamber
Cultivation and medium change (day 7, 8, 9)	Medium change ▼
Harvest and final formulation (day 10)	Semi-automated harvest of P2 PSCs Sample collection for QC and cell counting Storage of cells in the target cell bag
Post-process (day 10)	Tubing set deinstallation ▼
Quality control (> day 10)	PSC characterization (e.g. App note: Multicolor flow cytometry analysis of human pluripotent stem cell cultures¹) Trilineage differentiation potential of PSCs (e.g. StemMACS™ Trilineage Differentiation Kit, human²)
	10 days for total process


Principle of the PSC expansion process using the CliniMACS Prodigy®



CliniMACS Prodigy TS 730 setup for PSC expansion



Performance data



1×10⁶ cryopreserved human PSCs were initially seeded and cultured in the CliniMACS Prodigy® chamber until day 5 and further expanded in one Corning® CellSTACK® 5 Chamber from day 5 to day 10 in iPS-Brew GMP Medium using the CliniMACS Prodigy Adherent Cell Culture System. As a control, cells were cultured with manual laboratory standard using 6-well plates and T75 flasks. (A) After 10 days of expansion, a clinically relevant number of P2 PSCs (approx. 5×10⁸ cells) was harvested using the CliniMACS Prodigy Adherent Cell Culture System. The cumulative population doubling rate was comparable to the one obtained with manual laboratory standard. (B) Flow cytometry analysis confirmed the quality of PSCs processed with the CliniMACS Prodigy Adherent Cell Culture System. Harvested PSCs showed high expression levels of the key pluripotency markers Oct3/4, Sox2, TRA-1-60, and SSEA-4.

References

- Miltenyi Biotec (2016) Multicolor flow cytometry analysis of human pluripotent stem cell cultures. www.miltenyibiotec.com/flow-analysis-PSC
- Miltenyi Biotec (2017) StemMACS™ Trilineage Differentiation Kit Protocol for flow analysis. www.miltenyibiotec.com/Tri-Dif-Kit



Miltenyi Biotec Inc. | Phone 800 FOR MACS | Phone +1 530 888 8871 | Fax +1 877 591 1060 | macsus@miltenyi.com | **www.miltenyibiotec.com** Miltenyi Biotec provides products and services worldwide. Visit **www.miltenyibiotec.com/local** to find your nearest Miltenyi Biotec contact.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use.

MACS® GMP Products are for research use and ex vivo cell culture processing only, and are not intended for human in vivo applications. For regulatory status in the USA, please contact your local representative. MACS GMP Products are manufactured and tested under a quality system certified to ISO 13485 and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485. In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for in vitro use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.

In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or FDA approval. CliniMACS GMP MicroBeads are for research use and ex vivo cell processing only. CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. CentriCult, CliniMACS, CliniMACS, CliniMACS, the Miltenyi Biotec logo, and StemMACS are registered trademarks or trademarks of Miltenyi Biotec and/or its affiliates in various countries worldwide. All other trademarks mentioned in this document are the property of their respective owners and are used for identification purposes only. Copyright © 2020 Miltenyi Biotec and/or its affiliates. All rights reserved.